Brief: Kinnate Biopharma Reports FDA Clearance Of IND Application For KIN-2787

Kinnate Biopharma

17/05/2021 22:09

May 17 (Reuters) - Kinnate Biopharma Inc  KNTE.O :
    * KINNATE BIOPHARMA INC. REPORTS FIRST QUARTER 2021
FINANCIAL
RESULTS AND ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG
APPLICATION FOR KIN-2787
    * KINNATE BIOPHARMA INC - PLANNED INITIATION OF PHASE 1
CLINICAL
TRIAL FOR KIN-2787 IN MID-2021
    * KINNATE BIOPHARMA INC - ENDED QUARTER WITH CASH AND CASH
EQUIVALENTS AND INVESTMENTS OF $383.1 MILLION
    * KINNATE BIOPHARMA INC - QTRLY NET LOSS PER SHARE, BASIC
AND
DILUTED $0.40

Source text for Eikon:  ID:nGNX42FyRf 
Further company coverage:  KNTE.O 

 ((Reuters.Briefs@thomsonreuters.com;))